Ipamorelin Side Effects: What the Research Record Actually Shows

Ipamorelin's reputation is built on a selectivity claim: it triggers growth hormone release through the ghrelin receptor without dragging ACTH and cortisol along with it, unlike the older secretagogues GHRP-6, GHRP-2 and hexarelin. That claim is well supported in animal pharmacology. What it is not is a substitute for human safety data, and ipamorelin has only one completed human trial, run on hospitalized surgical patients rather than healthy adults self-dosing for research. This page sorts what is documented from what is inferred, covers the injection site and water retention effects that are standard across the secretagogue class, and is specific about what that one trial did and did not find.

Everything below is research use information. It is not medical advice, it is not a recommendation to start or stop anything, and none of it substitutes for supervision by a qualified clinician who can see your bloodwork and your history.

The Selectivity Claim, and What It Rests On

Ipamorelin is a pentapeptide that activates GHS-R1a, the ghrelin receptor, to trigger growth hormone release from the pituitary. The reason it displaced GHRP-6 and hexarelin in most protocols is a 1998 Novo Nordisk study (Raun and colleagues, European Journal of Endocrinology) showing that in conscious pigs, ipamorelin released growth hormone with a potency and peak response very close to GHRP-6, while ACTH and cortisol stayed at levels not significantly different from those seen after GHRH, the body's own growth hormone releasing hormone. That held even at doses more than two hundred times the ED50, the dose that produces half the maximal growth hormone response. In the same pigs, GHRP-6 and GHRP-2 both raised ACTH and cortisol. Prolactin is a different story from the one usually told: none of the secretagogues in that study, ipamorelin, GHRP-6 or GHRP-2, changed prolactin, LH, FSH or TSH. So the pig data separates ipamorelin from the older compounds on the cortisol axis; it does not show a prolactin difference either way.

The caveat is in the species and the dosing. That finding is animal pharmacology in pigs, not a result confirmed by a controlled human trial at the doses people actually run subcutaneously. The mechanism is credible and widely cited precisely because it has held up as the class moved from hexarelin to ipamorelin, but "no significant cortisol rise in pigs at more than 200 times the ED50" and "confirmed safe in humans" are different claims, and the record only supports the first one directly. The ipamorelin versus sermorelin comparison covers how this selectivity profile compares with a GHRH analog that works through an entirely different receptor.

The Appetite Question

Ghrelin's other main job, besides triggering growth hormone, is stimulating hunger, and GHRP-6 has a strong reputation in research forums for a hunger spike after a dose. A common claim is that ipamorelin's selectivity extends to appetite and that it leaves hunger alone. The animal data does not support that. In a 2009 rat study of postoperative ileus (Venkova and colleagues, Journal of Pharmacology and Experimental Therapeutics), a single intravenous dose of ipamorelin had no effect on food intake over the following 48 hours, but repeated dosing over two days significantly increased food intake and body weight gain. In a 2001 mouse study (Lall and colleagues), twice daily ipamorelin raised body fat, and secretagogue treatment, unlike growth hormone itself, increased food intake.

So users who notice more hunger on ipamorelin are describing something with a documented pharmacological basis in animals, not just expectation. What is missing is human data. The one human trial listed an appetite assessment among its secondary measures, but neither the published abstract nor FDA's 2024 review of the trial reports an appetite difference between the arms, and there is no controlled comparison of how strongly ipamorelin and GHRP-6 drive hunger in people. The fair summary is that increased appetite is a plausible, animal-documented effect of ipamorelin whose size in humans has not been measured.

Injection Site Reactions

This is the one to expect regardless of which secretagogue is in the syringe. Local redness, mild swelling, itching or tenderness is the most commonly reported complaint across subcutaneous peptides, and much of it is the injection rather than the compound: repeated injections irritate skin whatever is in the syringe.

Rotating sites, letting the alcohol dry fully, allowing cold material to warm first, using a fresh needle, and keeping the injected volume small all reduce local reaction. The injection guide covers rotation and technique, and the ipamorelin dosage calculator shows what volume a given vial strength and water volume produce. A reaction that spreads, blisters, hardens into a lasting lump, or arrives with fever is not ordinary irritation and is a reason to see a clinician.

Water Retention and Joint Aches

Mild fluid retention is the systemic effect reported most often across growth hormone secretagogues: puffiness in the hands or face, fullness or stiffness in the joints, occasionally carpal tunnel type numbness in the fingers, and a small scale weight increase in the first weeks that has nothing to do with tissue gained.

This follows from growth hormone and IGF-1 acting on sodium and water handling, not from anything specific to the ghrelin receptor, which is why sermorelin, CJC-1295 and ipamorelin all carry the same entry on their side effect lists despite working through different pituitary pathways. It tracks with how strongly an individual responds rather than with the micrograms injected, and it is more prominent at the top of the usual dose range. The ipamorelin dosage guide covers why doses above the saturating range do not raise the growth hormone pulse further, which caps how far this effect scales with dose alone.

What the One Human Trial Actually Found

Ipamorelin has exactly one completed human trial. Originally developed by Novo Nordisk, it was later taken into a phase 2, randomized, placebo controlled trial by Helsinn Therapeutics for postoperative ileus, the temporary gut paralysis that follows bowel surgery. The trial enrolled 117 hospitalized adults undergoing small or large bowel resection, dosed intravenously, with 114 included in the safety population. Patients received 0.03 mg/kg by intravenous infusion twice daily from the first day after surgery until day 7 or discharge, 56 on ipamorelin and 58 on placebo. The primary endpoint was time to tolerating a standardized solid meal: a median 25.3 hours on ipamorelin versus 32.6 hours on placebo, not a statistically significant difference (p = 0.15), and the secondary gut recovery measures did not separate either. Development for postoperative ileus was reportedly dropped after these disappointing results. The trial was published by Beck and colleagues in 2014 in the International Journal of Colorectal Disease.

The safety data from that trial is the only controlled human adverse event record ipamorelin has, so it is worth stating plainly. Any treatment emergent adverse event occurred in 87.5 percent of the ipamorelin group versus 94.8 percent on placebo, meaning the drug group reported fewer, not more, adverse events overall. Nausea, vomiting and abdominal distention were the most common complaints in both arms, which tracks with a population recovering from bowel surgery rather than with the drug. Three findings did come in higher on ipamorelin than placebo: hypokalemia, 12.5 percent versus 3.4 percent, insomnia, 10.7 percent versus 5.2 percent, and high blood glucose at discharge, 14.3 percent versus 8.6 percent.

Serious adverse events, mostly infections, anastomotic leaks and readmissions for wound complications, occurred in 17.9 percent of the ipamorelin group (10 patients) and 15.5 percent on placebo (9 patients), most of them after dosing had ended. Two patients on ipamorelin died, both colon cancer resections complicated by anastomotic leak. FDA's 2024 review of the trial, prepared for its Pharmacy Compounding Advisory Committee, says it is unclear whether those deaths were related to ipamorelin, but cites them together with the higher hypokalemia and hyperglycemia rates as a safety concern. Three patients in each arm stopped the drug early because of an adverse event.

Two caveats matter more than the numbers. First, this was intravenous dosing in acutely ill hospital inpatients recovering from bowel surgery, a different exposure and a different population from subcutaneous self-dosing in a healthy adult, so the rates above describe that setting and should not be read as the expected profile for research use. Second, a surgical population already runs a high baseline rate of nausea, vomiting, electrolyte shifts and sleep disruption, which is almost certainly why even the placebo arm's adverse event rate was so high. With 56 patients on the drug, the gaps above come down to a handful of people each and the trial was not powered to show they are real. Still, hypokalemia, insomnia and high glucose are the instances where ipamorelin came in above placebo, and they are the closest thing to a specific human safety signal this compound has, even filtered through a very different clinical context.

Cortisol, Prolactin and Glucose, Restated

Cortisol and prolactin. Covered above: well supported in animal pharmacology, not confirmed by a controlled human trial at research doses. Neither the published abstract of the postoperative ileus trial nor FDA's review of it mentions cortisol or prolactin results, so the one human trial adds nothing either way on this question.

Glucose. This one is real in principle for any growth hormone secretagogue, because growth hormone is counter-regulatory to insulin. Ipamorelin's one human trial did record a glucose signal: high blood glucose at discharge in 14.3 percent of the ipamorelin group versus 8.6 percent on placebo. That trial ran for days, not weeks, in patients under acute surgical stress that already disrupts glucose handling, so it says little about sustained use, but it points the same direction as the mechanism. The practical point stands regardless: anyone with existing glucose dysregulation has a real reason to be supervised rather than to guess. The ipamorelin versus tesamorelin comparison covers how uneven the trial evidence is between a GHRH analog with a well characterized glucose signal from multiple trials and a GHRP with one small surgical trial.

The Long Term Question, Stated Plainly

There is no multi year controlled follow up of ipamorelin in any population, including the one it was tested in. The postoperative ileus trial ran over the course of a hospital stay, dosing stopped at day 7 or discharge, and development was reportedly dropped after it missed its efficacy endpoint, so nobody extended it into longer dosing. So the accurate statement is that long term ipamorelin side effects are unknown, not that they are absent. The concern that would need such a study is the same one attached to any growth hormone secretagogue: sustained IGF-1 elevation.

Who Should Not Use It, and Why Supervision Matters

Some categories are not close calls. An active or recent malignancy is the clearest, because IGF-1 is a growth signal and deliberately raising it is not a decision to make informally. Pregnancy and breastfeeding have no safety data. Uncontrolled glucose dysregulation and active diabetic retinopathy are reasons for caution given the insulin relationship. Untreated thyroid or adrenal dysfunction means the growth hormone axis is not behaving normally to begin with. People under eighteen, and anyone on a medication list touching the endocrine system, belong in a clinician's office rather than a forum thread.

There is also a risk that has nothing to do with the molecule. Ipamorelin sold as a research chemical carries no assurance of identity, purity or sterility, and a contaminated or mislabelled vial produces problems no careful dosing prevents. The general peptide side effects page makes the case that supply quality is often the larger variable, which matters here because the one human trial used a pharmaceutical-grade IV formulation, not the lyophilised research vials most people are actually injecting.

Dose and What to Monitor

The practical implication of a thin human record is that titration and monitoring do more work than usual. Starting at the low end of the usual range and moving only if it does nothing keeps exposure down while the research record stays this sparse. The ipamorelin dosage guide covers the saturating dose effect and why more micrograms past a certain point does not raise the growth hormone pulse further.

Worth having measured, with a clinician reading the results: IGF-1 at baseline and again after a couple of months, fasting glucose and HbA1c, and potassium, given the hypokalemia and glucose signals in the one trial that exists. Worth recording yourself: injection sites and reactions, morning weight, ring or shoe fit as a crude fluid proxy, sleep quality, and any joint symptoms with dates.

Frequently Asked Questions

Is ipamorelin safe?

Safe is the wrong shape of word for a compound with one completed human trial, and that trial used IV dosing in hospitalized surgical patients rather than the subcutaneous self-dosing most research use looks like. What exists is a strong receptor selectivity argument from animal pharmacology, one small human trial in which overall adverse events were lower than placebo but hypokalemia, insomnia, high glucose and serious adverse events were numerically higher, with two deaths on ipamorelin that FDA calls of unclear relation to the drug, and no controlled human data for the way it is actually used. That is a mixed picture with real gaps in it, not a safety guarantee.

Does ipamorelin raise cortisol or prolactin?

The selectivity claim rests mainly on a 1998 animal study showing ipamorelin triggered growth hormone release without raising ACTH or cortisol beyond what GHRH produced, even at more than two hundred times the ED50 for growth hormone release, while GHRP-6 and GHRP-2 raised both. Prolactin did not move with any of the compounds in that study, so the pig data shows no prolactin difference either way; it does not establish one. That finding is well regarded and is why ipamorelin displaced the older secretagogues in most protocols. It is pig data, not a confirmed result from a controlled human trial at the doses people run, so the honest claim is well supported rather than proven in humans.

Does ipamorelin increase appetite?

It can. Ipamorelin acts on the same ghrelin receptor that drives hunger, and its selectivity does not clearly extend to appetite: in a 2009 rat study, repeated intravenous ipamorelin significantly increased food intake and body weight gain, and in mice ipamorelin raised body fat alongside higher food intake. No human trial has reported an appetite effect either way, and how it compares with GHRP-6 in people has not been measured, so increased hunger is a plausible effect rather than a myth.

What side effects showed up in the ipamorelin clinical trial?

The only completed human trial, a 2014 phase 2 study in bowel resection patients, reported adverse events in 87.5 percent of the ipamorelin group versus 94.8 percent on placebo, with nausea, vomiting and abdominal distention common in both arms because the trial population was recovering from surgery. Three findings came in higher on ipamorelin than placebo: hypokalemia, 12.5 percent versus 3.4 percent, insomnia, 10.7 percent versus 5.2 percent, and high blood glucose at discharge, 14.3 percent versus 8.6 percent. Serious adverse events ran 17.9 percent versus 15.5 percent, and two patients on ipamorelin died after anastomotic leaks, deaths FDA says are of unclear relation to the drug. The trial used intravenous dosing in acutely ill hospital patients, a different setting from subcutaneous self-dosing in healthy adults, so the numbers describe that population, not research use.

What are the long term side effects of ipamorelin?

Nobody has the data to answer this for healthy adults. The one completed human trial ran for days around a surgical recovery, not months or years, and development was reportedly dropped after it missed its primary efficacy endpoint rather than continued into longer dosing. Long term ipamorelin side effects are unknown rather than absent, and the concern that would need a multi year study is the same one attached to any growth hormone secretagogue: sustained IGF-1 elevation.